Robert Lanza Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert Lanza.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert Lanza. Robert Lanza is Chief Scientific Officer in Ocata Therapeutics, Inc. ($ACTC).
Latest Insider Trading Transactions of Robert Lanza
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 8.49 | 76,666 | 650,894 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 8.49 | 35,334 | 299,986 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 6.20 | 12,858 | 79,720 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 15.70 | 150,000 | 2,355,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 19.50 | 17,834 | 347,763 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 9.80 | 53,500 | 524,300 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | D | 21.00 | 40,000 | 840,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | U | 8.50 | 231,509 | 1,967,827 | 0 | 231.5 K to 0 (-100.00 %) |
| Nov 10 2015 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.36 | 10,000 | 83,600 | 196,509 | 206.5 K to 196.5 K (-4.84 %) |
| Nov 10 2015 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.36 | 10,000 | 83,600 | 206,509 | 216.5 K to 206.5 K (-4.62 %) |
| Nov 10 2015 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 8.25 | 15,000 | 123,750 | 216,509 | 231.5 K to 216.5 K (-6.48 %) |
| May 21 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.07 | 600,000 | 39,300 | 29,153,180 | 29.8 M to 29.2 M (-2.02 %) |
| Apr 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Option Exercise | A | 0.10 | 5,350,000 | 524,300 | 5,350,000 | |
| Apr 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.09 | 400,000 | 36,000 | 29,753,180 | 30.2 M to 29.8 M (-1.33 %) |
| Apr 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.09 | 25,000 | 2,225 | 30,153,180 | 30.2 M to 30.2 M (-0.08 %) |
| Apr 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Sell | S | 0.09 | 14,023 | 1,276 | 30,178,180 | 30.2 M to 30.2 M (-0.05 %) |
| Apr 23 2010 | ACTC | Ocata Therapeutics ... | Lanza Robert | Chief Scientific Of ... | Grant | A | 0.00 | 30,192,203 | 0 | 30,192,203 | 0 to 30.2 M |
Page: 1